[go: up one dir, main page]

WO2008036254A3 - Autophagic compounds and tyrosine kinase inhibitors for treating cancer - Google Patents

Autophagic compounds and tyrosine kinase inhibitors for treating cancer Download PDF

Info

Publication number
WO2008036254A3
WO2008036254A3 PCT/US2007/020179 US2007020179W WO2008036254A3 WO 2008036254 A3 WO2008036254 A3 WO 2008036254A3 US 2007020179 W US2007020179 W US 2007020179W WO 2008036254 A3 WO2008036254 A3 WO 2008036254A3
Authority
WO
WIPO (PCT)
Prior art keywords
autophagic
compounds
tyrosine kinase
treating cancer
kinase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/020179
Other languages
French (fr)
Other versions
WO2008036254A2 (en
Inventor
Jeffrey Settleman
Sreenath V Sharma
Ultan Mcdermott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of WO2008036254A2 publication Critical patent/WO2008036254A2/en
Publication of WO2008036254A3 publication Critical patent/WO2008036254A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides combinations of autophagy modulators and inhibitors of the epidermal growth factor receptor and methods of using these combinations for the treatment subjects having cancer.
PCT/US2007/020179 2006-09-18 2007-09-18 Autophagic compounds and tyrosine kinase inhibitors for treating cancer Ceased WO2008036254A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84531106P 2006-09-18 2006-09-18
US60/845,311 2006-09-18

Publications (2)

Publication Number Publication Date
WO2008036254A2 WO2008036254A2 (en) 2008-03-27
WO2008036254A3 true WO2008036254A3 (en) 2008-05-08

Family

ID=39201055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/020179 Ceased WO2008036254A2 (en) 2006-09-18 2007-09-18 Autophagic compounds and tyrosine kinase inhibitors for treating cancer

Country Status (1)

Country Link
WO (1) WO2008036254A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137844A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US9572820B2 (en) 2011-05-10 2017-02-21 Stc.Unm Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
GB2584441A (en) * 2019-06-03 2020-12-09 Fenomark Diagnostics Ab Medical uses, methods and uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAO ET AL.: "Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GMB cells", NEOPLASIA, vol. 7, October 2005 (2005-10-01), pages 921 - 929 *

Also Published As

Publication number Publication date
WO2008036254A2 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
AU2009270856A8 (en) Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
MX2009008347A (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
NO20060398L (en) Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for the treatment and inhibition of cancer
WO2009025806A3 (en) Use of vegfr-2 inhibitors for treating metastatic cancer
IL195152A0 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
EP2100614B8 (en) Antibody against PDGFR-alpha for use in the treatment of tumours
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
GB0504988D0 (en) Device and method for the treatment of diseased tissue such as tumors
WO2011046964A3 (en) Inhibitors of bruton's tyrosine kinase
EP2532657A3 (en) Compounds and methods of use
GEP20115283B (en) Pyrrolopyrimidine compounds and their uses
EA201000016A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND DISTURBANCES ASSOCIATED WITH TUMORS
MY152948A (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2007111904A3 (en) C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2004100947A3 (en) Novel chemical compounds
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2008027837A3 (en) Small molecule potentiator of hormonal therapy for breast cancer
WO2010048026A3 (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
EG25039A (en) Process for preparation of compounds used for inhibition of one or more tyrosine kinases.
AP2010005357A0 (en) 6.7-dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
UA100545C2 (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
IL184997A0 (en) Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838396

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07838396

Country of ref document: EP

Kind code of ref document: A2